Nanoparticle-mediated drug delivery system for pulmonary arterial hypertension

Journal of Clinical Medicine

Volumn 6, Issue 5, 2017, Pages

  Nakamura, Kazufumi ^a   Matsubara, Hiromi ^b   Akagi, Satoshi ^a   Sarashina, Toshihiro ^a   Ejiri, Kentaro ^a   Kawakita, Norifumi ^a   Yoshida, Masashi ^a   Miyoshi, Toru ^a   Watanabe, Atsuyuki ^a   Nishii, Nobuhiro ^a   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Drug delivery system; Nanoparticle; Prostacyclin; Pulmonary arterial hypertension

Indexed keywords

BERAPROST; CYTOKINE; FASUDIL; FLUORESCEIN ISOTHIOCYANATE; IMATINIB; LIPOSOME; MONOCROTALINE; NANOCARRIER; NANOPARTICLE; PITAVASTATIN; PROSTACYCLIN; PROTEIN TYROSINE KINASE INHIBITOR; SOLID LIPID NANOPARTICLE; UMIN000014940; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTERIAL SMOOTH MUSCLE CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GENE EXPRESSION; HEADACHE; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HYPOTENSION; HYPOXIA; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; MONOCROTALINE-INDUCED PULMONARY HYPERTENSION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

EID: 85032217683     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm6050048     Document Type: Review

References (33)

1. Archer, S.; Rich, S. Primary pulmonary hypertension: A vascular biology and translational research “Work in progress”. Circulation 2000, 102, 2781–2791. [CrossRef] [PubMed]
2. Miura, A.; Nakamura, K.; Kusano, K.F.; Matsubara, H.; Ogawa, A.; Akagi, S.; Oto, T.; Murakami, T.; Ohtsuka, A.; Yutani, C.; et al. Three-dimensional structure of pulmonary capillary vessels in patients with pulmonary hypertension. Circulation 2010, 121, 2151–2153. [CrossRef] [PubMed]
3. Jorge, E; Baptista, R.; Calisto, J.; Faria, H.; Monteiro, P.; Pan, M.; Pego, M. Optical coherence tomography of the pulmonary arteries: A systematic review. J. Cardiol. 2016, 67, 6–14. [CrossRef] [PubMed]
4. Akagi, S.; Nakamura, K.; Miyaji, K.; Ogawa, A.; Kusano, K.F.; Ito, H.; Matsubara, H. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ. J. 2010, 74, 2200–2205. [CrossRef] [PubMed]
5. Saito, Y.; Nakamura, K.; Akagi, S.; Sarashina, T.; Ejiri, K.; Miura, A.; Ogawa, A.; Matsubara, H.; Ito, H. Epoprostenol sodium for treatment of pulmonary arterial hypertension. Vasc. Health Risk Manag. 2015, 11, 265–270. [PubMed]
6. Galie, N.; Corris, P.A.; Frost, A.; Girgis, R.E.; Granton, J.; Jing, Z.C.; Klepetko, W.; McGoon, M.D.; McLaughlin, V.V.; Preston, I.R.; et al. Updated treatment algorithm of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2013, 62, D60–D72. [CrossRef] [PubMed]
7. Galie, N.; Humbert, M.; Vachiery, J.L.; Gibbs, S.; Lang, I.; Torbicki, A.; Simonneau, G.; Peacock, A.; Vonk Noordegraaf, A.; Beghetti, M.; et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016, 37, 67–119. [PubMed]
8. Matsubara, H.; Ogawa, A. Treatment of idiopathic/hereditary pulmonary arterial hypertension. J. Cardiol. 2014, 64, 243–249. [CrossRef] [PubMed]
9. Tokunaga, N.; Ogawa, A.; Ito, H.; Matsubara, H. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. J. Cardiol. 2016, 68, 542–547. [CrossRef] [PubMed]
10. Akagi, S.; Nakamura, K.; Matsubara, H.; Kusano, K.F.; Kataoka, N.; Oto, T.; Miyaji, K.; Miura, A.; Ogawa, A.; Yoshida, M.; et al. Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int. J. Cardiol. 2013, 165, 499–505. [CrossRef] [PubMed]
11. Oudiz, R.J.; Widlitz, A.; Beckmann, X.J.; Camanga, D.; Alfie, J.; Brundage, B.H.; Barst, R.J. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 2004, 126, 90–94. [CrossRef] [PubMed]
12. Ogawa, A.; Nakamura, K.; Matsubara, H.; Fujio, H.; Ikeda, T.; Kobayashi, K.; Miyazaki, I.; Asanuma, M.; Miyaji, K.; Miura, D.; et al. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation 2005, 112, 1806–1812. [CrossRef] [PubMed]
13. Fujio, H.; Nakamura, K.; Matsubara, H.; Kusano, K.F.; Miyaji, K.; Nagase, S.; Ikeda, T.; Ogawa, A.; Ohta-Ogo, K.; Miura, D.; et al. Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J. Cardiovasc. Pharmacol. 2006, 47, 250–255. [CrossRef] [PubMed]
14. Schermuly, R.T.; Dony, E.; Ghofrani, H.A.; Pullamsetti, S.; Savai, R.; Roth, M.; Sydykov, A.; Lai, Y.J.; Weissmann, N.; Seeger, W.; et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Investig. 2005, 115, 2811–2821. [CrossRef] [PubMed]
15. Nakamura, K.; Akagi, S.; Ogawa, A.; Kusano, K.F.; Matsubara, H.; Miura, D.; Fuke, S.; Nishii, N.; Nagase, S.; Kohno, K.; et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int. J. Cardiol. 2012, 159, 100–106. [CrossRef] [PubMed]
16. Ghofrani, H.A.; Seeger, W.; Grimminger, F. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2005, 353, 1412–1413. [CrossRef] [PubMed]
17. Hatano, M.; Yao, A.; Shiga, T.; Kinugawa, K.; Hirata, Y.; Nagai, R. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int. Heart J. 2010, 51, 272–276. [CrossRef] [PubMed]
18. Hoeper, M.M.; Barst, R.J.; Bourge, R.C.; Feldman, J.; Frost, A.E.; Galie, N.; Gomez-Sanchez, M.A.; Grimminger, F.; Grunig, E.; Hassoun, P.M.; et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation 2013, 127, 1128–1138. [CrossRef] [PubMed]
19. Kim, B.Y.; Rutka, J.T.; Chan, W.C. Nanomedicine. N. Engl. J. Med. 2010, 363, 2434–2443. [CrossRef] [PubMed]
20. Matoba, T.; Egashira, K. Nanoparticle-mediated drug delivery system for cardiovascular disease. Int. Heart J. 2014, 55, 281–286. [CrossRef] [PubMed]
21. Vaidya, B.; Gupta, V. Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery. J. Control. Release 2015, 211, 118–133. [CrossRef] [PubMed]
22. Chen, L.; Nakano, K.; Kimura, S.; Matoba, T.; Iwata, E.; Miyagawa, M.; Tsujimoto, H.; Nagaoka, K.; Kishimoto, J.; Sunagawa, K.; et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 2011, 57, 343–350. [CrossRef] [PubMed]
23. Kimura, S.; Egashira, K.; Chen, L.; Nakano, K.; Iwata, E.; Miyagawa, M.; Tsujimoto, H.; Hara, K.; Morishita, R.; Sueishi, K.; et al. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 2009, 53, 877–883. [CrossRef] [PubMed]
24. Akagi, S.; Nakamura, K.; Miura, D.; Saito, Y.; Matsubara, H.; Ogawa, A.; Matoba, T.; Egashira, K.; Ito, H. Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension. Int. Heart J. 2015, 56, 354–359. [CrossRef] [PubMed]
25. Ishihara, T.; Hayashi, E.; Yamamoto, S.; Kobayashi, C.; Tamura, Y.; Sawazaki, R.; Tamur, F.; Tahara, K.; Kasahara, T.; Ishihara, T.; et al. Encapsulation of beraprost sodium in nanoparticles: Analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension. J. Control. Release 2015, 197, 97–104. [CrossRef] [PubMed]
26. Akagi, S.; Nakamura, K.; Matsubara, H.; Kondo, M.; Miura, D.; Matoba, T.; Egashira, K.; Ito, H. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension. J. Cardiovasc. Pharmacol. 2016, 67, 290–298. [CrossRef] [PubMed]
27. Gupta, V.; Gupta, N.; Shaik, I.H.; Mehvar, R.; McMurtry, I.F.; Oka, M.; Nozik-Grayck, E.; Komatsu, M.; Ahsan, F. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. J. Control. Release 2013, 167, 189–199. [CrossRef] [PubMed]
28. McLendon, J.M.; Joshi, S.R.; Sparks, J.; Matar, M.; Fewell, J.G.; Abe, K.; Oka, M.; McMurtry, I.F.; Gerthoffer, W.T. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J. Control. Release 2015, 210, 67–75. [CrossRef] [PubMed]
29. Shimokawa, H.; Satoh, K. 2015 ATVB Plenary Lecture: Translational research on rho-kinase in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol 2015, 35, 1756–1769. [CrossRef] [PubMed]
30. Abe, K.; Shimokawa, H.; Morikawa, K.; Uwatoku, T.; Oi, K.; Matsumoto, Y.; Hattori, T.; Nakashima, Y.; Kaibuchi, K.; Sueishi, K.; et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res 2004, 94, 385–393. [CrossRef] [PubMed]
31. Abe, K.; Tawara, S.; Oi, K.; Hizume, T.; Uwatoku, T.; Fukumoto, Y.; Kaibuchi, K.; Shimokawa, H. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J. Cardiovasc. Pharmacol. 2006, 48, 280–285. [CrossRef] [PubMed]
32. Ahmad, M.Z.; Akhter, S.; Mallik, N.; Anwar, M.; Tabassum, W.; Ahmad, F.J. Application of decoy oligonucleotides as novel therapeutic strategy: A contemporary overview. Curr. Drug Discov. Technol. 2013, 10, 71–84. [PubMed]
33. Davidson, B.L.; McCray, P.B., Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011, 12, 329–340.